Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Phase 1 Completed 24 enrolled Allergan MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

Compare the acute effects and tolerability of Dihydroergotamine Mesylate (DHE) delivered by Oral Inhalation (MAP0004) versus by intravenous (IV) infusion in healthy adult volunteers.

Timeline

Start: 2010-03
Primary completion: 2010-09
Completion: 2010-12

Publications

Noveck RJ, Douglas PS, Chow SC, Mangum B, Kori S, Kellerman DJ. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. Drug Des Devel Ther. 2013 Jul 24;7:619-25. doi: 10.2147/DDDT.S44093. Print 2013.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dihydroergotamine	Small molecule	1 mg	Inhaled

Indications

No indication recorded.